18.32
-0.08(-0.43%)
Currency In USD
| Previous Close | 18.4 |
| Open | 18.68 |
| Day High | 19.1 |
| Day Low | 18.28 |
| 52-Week High | 19.5 |
| 52-Week Low | 9.03 |
| Volume | 768,732 |
| Average Volume | 532,293 |
| Market Cap | 1.38B |
| PE | -18.69 |
| EPS | -0.98 |
| Moving Average 50 Days | 15.7 |
| Moving Average 200 Days | 13.58 |
| Change | -0.08 |
If you invested $1000 in Zymeworks Inc. (ZYME) since IPO date, it would be worth $1,409.23 as of October 20, 2025 at a share price of $18.32. Whereas If you bought $1000 worth of Zymeworks Inc. (ZYME) shares 5 years ago, it would be worth $423.39 as of October 20, 2025 at a share price of $18.32.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025
GlobeNewswire Inc.
Oct 16, 2025 10:00 AM GMT
VANCOUVER, British Columbia, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for diffic
Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference
GlobeNewswire Inc.
Oct 13, 2025 8:00 PM GMT
Preliminary data presented at the AACR-NCI-EORTC conference will provide insights into the potential of ZW191 in patients with advanced solid tumors, including ovarian cancer, endometrial cancer, and non-small cell lung cancer.Data from the Phase 1 t
Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer
GlobeNewswire Inc.
Oct 09, 2025 10:00 AM GMT
VANCOUVER, British Columbia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficu